1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021

Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021

  • May 2021
  • 190 pages
  • ID: 6089308
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Wet Age-Related Macular Degeneration (Wet-AMD) Understanding

Wet Age-Related Macular Degeneration (Wet-AMD): Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type.
Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision.
The complaints of a patient with wet AMD may vary from metamorphopsia, central or paracentral scotoma, to a sudden, nonspecific reduction in central vision. Common symptoms of wet AMD include: Distortion of straight lines (metamorphopsia), a blind spot or hole in one’s vision (scotoma), difficulty with adaptation to the dark.
Age-related macular degeneration is defined by fundus examination, but the diagnosis of AMD is typically based on age, clinical findings through various tests like Color fundus photography, Fluorescein angiography and/or Optical coherence tomography. Color photography and fluorescein angiography are done when findings suggest wet AMD. A simple test for daily monitoring of vision in patients with AMD is the Amsler grid. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches for Wet Age-Related Macular Degeneration (Wet-AMD).

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters
This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs
• SOK583A1: Sandoz
Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz. In May 2021, Sandoz announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT—a clinical Phase III confirmatory efficacy and safety study.
• SB15: Samsung Bioepis
SB15 is being developed as a biosimilar to the reference product Eylea (aflibercept)—an anti-VEGF drug.
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Samsung Bioepis. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the US, Canada, Europe, Japan, and Australia.
Further product details are provided in the report……..

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment
This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Wet Age-Related Macular Degeneration (Wet-AMD)
There are approx. 70+ key companies which are developing the Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.
• Phases
This report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights
• Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration (Wet-AMD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Sandoz
• Sam Chun Dang Pharm
• Samsung Bioepis
• Opthea Limited
• Luye Pharma
• Shanghai Henlius Biotech
• Generium Pharmaceuticals
• Bioeq GmbH
• Roche
• Chong Kun Dang Pharmaceutical
• Outlook Therapeutics
• Kodiak Sciences
• Amgen
• Qilu Pharmaceuticals
• Xbrane Biopharma
• Regenxbio
• Formycon
• Dobecure
• Gemini Therapeutics
• Isarna Therapeutics
• AngioLab Inc
• Alkahest
• Tyrogenex
• IVERIC bio (formerly Ophthotech Corporation)
• Tasly Pharmaceutical Group
• Ribomic
• Innovent Biologics
• Gemini Therapeutics
• GrayBug Vision
• Curacle
• Quark Pharmaceuticals
• Bio-Thera Solutions
• RemeGen
• Sinocelltech
• PanOptica
• Clearside Biomedical
• AsclepiX Therapeutics
• Feramda
• AiViva BioPharma
• Unity Biotechnology
• Kyowa Kirin
• Ocular Therapeutix
• Janssen Research & Development
• Huabo Biopharm
• EyePoint Pharmaceuticals
• Shanghai Biomabs Pharmaceutical
• Ashvattha Therapeutics
• Samjin Pharm
• Akari Therapeutics
• Eyevensys
• PharmAbcine
• Neurophth Therapeutics
• Ocugen

Key Products
• SOK583A1
• SCD411
• SB15
• OPT-302
• LY09004
• HLX04-O
• GNR-067
• FYB203
• Faricimab
• CKD-701
• ONS-5010
• KSI-301
• ABP 938
• BCD 300
• Xlucane
• RGX-314
• FYB201
• Etamsylate
• GEM-103
• ISTH0036
• ALS-L1023
• AKST4290
• Vorolanib (X-82)
• Zimura
• Sanhuangjingshimingwan
• RBM-007
• IBI302
• GEM103
• GB-102
• CU03
• PF-04523655
• BAT5906
• RC 28 E
• SCT510A
• PAN 90806
• CLS-AX
• AXT107
• AS101
• AIV007
• UBX1325
• KHK4951
• OTX-TKI
• AAVCAGsCD59
• HB002.1M
• EYP-1901
• CMAB818
• D-4517
• SJP1803/1804
• Nomacopan
• EYS609
• EYS809
• PMC-309
• PMC-403
• NFS-10
• OCU 200

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on